Therefore Substantial benzethonium contamination is always present in the process through to the end product itself with consequent loSS of purity, effects on the colour of the product and on its Stability, and presumably on its toxicity.
SUMMARY OF THE INVENTION
0006 The object of the present invention is essentially to improve the preparative method of EP 40144 in order to obtain final products of higher purity and without colour. 0007 To achieve this objective, as well as other advan tages which will be described hereinafter, the present inven tion presents a process for preparing high purity low 0017 Production of enoxaparin by means of isolating heparin benzethonium Salt on filter-aid, forming heparin benzyl ester sodium salt on filter-aid, hydrolysis of the benzyl ester Supported on filter-aid and isolation of enox aparin. 0023 The cake is then transferred into a reactor in which it is crushed by shaking vigorously with 200 litres of a 1 M solution of NaCl for 6 hours at a temperature of 50-56 C. 0024. The precipitate is collected in a centrifuge, the filtrate is discarded and the Washing procedure is repeated three times with 180 litres of hot water each time. Washing is repeated until the final washing solution (diluted 1 to 10) has an absorbance at 270 nm of <0.5. (60x0.75) and TSK3000 SW (60x0.75) and UV detector at 205 nm) and contaminated with nucleic acids (of which, in accordance with the European Pharmacopoeia test, a Solu tion of 40 mg in 10 ml water has an absorbance at 260 and 280 nm greater than 0.750 and 0.540 respectively) are subjected to Salification with 267 g benzethonium chloride on 100 g of filter aid (Diacel CF/S(R) under the conditions described in example 1a. At the end of the reaction the precipitate is collected by buckner funnel and pressed under vacuum. The cake is resuspended in 2.5 litres of a 0.5 M NaCl Solution and stirred for 1 hour at 50 C., filtered again and pressed in a buckner funnel. The cake is again resus pended in 2.5 litres of a 1M NaCl Solution and stirred for 1 hour at 50 C., then refiltered and resuspended in 2. 0045) 800 ml of 1 N sodium hydroxide and water are added to the Solution in order to bring the ester concentration to about 10% and the normality of the sodium hydroxide to approximately s(). 1 N. The mixture is heated to 60° C. 0046) The reaction proceeds for 45 minutes during which time the pH is checked to ensure it remains 211.0. If necessary Sodium hydroxide is added, the Solution is cooled and neutralised with 0.1 N hydrochloride acid. The solution is filtered. Sodium acetate is added to the filtrate in an quantity sufficient to achieve 12% (w/v) and the pH is adjusted to 6.0+0.2, after which it is precipitated with three Mar. 3, 2005 the esterification of example 1c, industrial batches were obtained from which samples HL 2709, HL 2710, HL 2711 respectively were withdrawn, either for analytical charac terisation or for examining the hydrolysis proceSS in con nection with their degree of esterification. 0049. The purity of said samples was estimated after extracting all water Soluble material from the filter-aid and measuring the resultant Solution on HPSEC, by comparing the area under the curve of the Sample under examination with an in-house reference consisting of heparin. 0050. The quantity of filter-aid was determined after extraction of Solubles, Washing the filter aid, drying and Weighing, 0051. The content of NaOAc contaminant was deter mined by HPSEC, or by ionic HPLC on anionic exchange columns and conductability detector (DXCOO Dionex). in the column "benzyl concentration' values in ppm are given, expressed on the crude ester containing filter-aid and sodium acetate. The 8.69% value was obtained in relation to ester purity (44%).
0060. The hydrolysis stage comprises at least two reac tions:
0061 ester hydrolysis reaction, prevailing 0062 B-elimination reaction, concurrent 0.063. The reaction which leads to depolymerisation is essentially B-elimination. To achieve a MWw ~4500 it is sufficient that out of about 15-16 esterified carboxyls only about 3 carboxyls are cleaved. 0.064 Possibly, therefore, the parameter which controls this stage of the process is not only the degree of esterifi cation of the benzyl ester intermediate, given that, on the same batch LE 2710 with a 8.69% degree of esterification, it is observed that a molecular weight of 4141 is obtained only with 0.1 N NaOH (and not 1 N) and only at a temperature of 60° C. (see LE2710 a in particular). 0065. With the same ester at 0° C. and at 85°C. 0075) Elute at 5 cm/min (for a filled column: Ø20x85 cm the Suggested flow is 1.6 litres/min), maintaining the pH of the eluate at 6.5-1.0 with acetic acid diluted 1:2. Wash the column until the refractive index=0 (about 0.6 V of the column) then add NaOAc (12% on the volume), adjust pH to 6.0+0.2, filter sterilely on sterile membranes, then pre cipitate with 3 VN of MeOH. 0076 Leave to decant for at least one night then siphon off the Supernatant, filter off the precipitate and wash with a Solution of Sodium acetate in MeOH.
0077. The elimination of acetate and residual solvents, by Washing with ethanol, drying and packaging, follow Stan dard procedures. 0078 By means of the aforedescribed purification a batch of enoxaparin 40100/B is obtained whose 10% solution is less coloured than the reference Solution BY7 in accordance with the European Pharmacopoeia test.
0079 Based on the experimental observations derived from the aforementioned examples, it can be added that in general, in addition to the aforedescribed principle advan tages, in accordance with the process of the present inven tion, it has also been found that an adequate depolymerisa tion conformity, i.e. the ideal balance between high and low molecular weights to achieve the best activity, is not depen dent So much on the degree of esterification rather, for the Same degree of esterification, on the temperature and con centration of the base used in the hydrolysis. It should also be noted that depolymerisation occurs in Solution, while the percentages of fractions of MW.<2000=12% to 20% and fractions of MW>8000=5% to 20% are specifications of the pure product, finished and isolated in the Solid State. It has also been found that Said specifications can be set for the product in the isolating Stage by means of 0080 Sufficient saline concentrations of NaCl or NaOAc and a Sufficient ratio of water and acetone miscible alcohol antisolvents, Such as for example 0081) adjusting the direct correlation between increased concentration of electrolytes in Solution and antisolvent Volumes and a greater percentage of precipitable lower molecular weight fractions. 1. Process for preparing high purity low molecular weight heparins with average molecular weight of between 2000 and 10000 daltons by the stages of forming an intermediate heparin benzethonium Salt, from this latter a water Soluble heparin ester, and of Subjecting said ester to depolymerisa tion with bases to form Said low molecular weight heparins, characterised in that at least Said Stage of heparin benzetho nium Salt formation is carried out on an inert adsorbent Solid matrix of filtering material, or filter-aid, Said low molecular weight heparins being finally Subjected to a purification Stage by reducing the impurities present with borohydride.
2. ProceSS as claimed in claim 1, wherein the Stages of forming an intermediate heparin benzethonium Salt, from this latter a water Soluble heparin ester, and of Subjecting Said ester to depolymerisation with bases to form said low molecular weight heparins are conducted on an inert adsor bent Solid matrix of filtering material, or filter-aid.
3. ProceSS as claimed in claim 1, wherein Said filtering material, or filter-aid, is chosen from coadjuvants used in polymer filtration, diatomaceous earth, perlite, Europerl 500, Diacel CF/S. Mar. 3, 2005 4. Process as claimed in claim 1, wherein the Stage of forming a water Soluble ester of heparin is conducted with a degree of esterification of said ester of less that 9.5%.
5. Process as claimed in claim 1, wherein the Stage of reducing with borohydride is conducted with NaBH in water at pH 8.2 to 8.6.
6. Process as claimed in claim 1, wherein Said low molecular weight heparin is enoxaparin with a dermatan Sulfate impurity of less than 0.04%, Said Stages comprising isolating heparin benzethonium Salt on filter-aid, forming heparin benzyl ester Sodium Salt on filter-aid, hydrolysis of the benzyl ester Supported on filter-aid, isolating enoxaparin with removal of Said filter-aid and purifying the enoxaparin thus obtained by reacting with borohydride.
7. Process as claimed in claim 4, wherein said low molecular weight heparin is enoxaparin with a dermatan Sulfate impurity of less than 0.04%, Said Stages comprising isolating heparin benzethonium Salt on filter-aid, forming heparin benzyl ester Sodium Salt on filter-aid with a degree of esterification of said ester of less than 9.5%, hydrolysis of the benzyl ester Supported on filter-aid, isolating enoxaparin with removal of Said filter-aid and purifying the enoxaparin thus obtained by reacting with borohydride.
8. Process as claimed in claim 6 wherein said low molecular weight heparin is enoxaparin with an average molecular weight of between 3500 and 5500 daltons.
9. Process as claimed in claim 7 wherein said low molecular weight heparin is enoxaparin with an average molecular weight of between 3500 and 5500 daltons.
10. Process as claimed in claim 8 wherein said low molecular weight heparin is enoxaparin with fractions of molecular weight less than 2000 daltons between 12% and 20% and fractions of molecular weight within the range 2000 to 8000 daltons between 68% and 88%. 11. Process as claimed in claim 9 wherein said low molecular weight heparin is enoxaparin with fractions of molecular weight less than 2000 daltons between 12% and 20% and fractions of molecular weight within the range 2000 to 8000 daltons between 68% and 88%.
